Actively Recruiting
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2025-07-09
12
Participants Needed
1
Research Sites
168 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.
CONDITIONS
Official Title
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years, any gender
- Newly diagnosed pancreatic cancer with liver metastases confirmed by pathology or clinical diagnosis
- No metastases to organs other than the liver
- Tumors visible on imaging and safely reachable for puncture
- Three or fewer tumors in half of the liver, each tumor 3 cm or smaller
- ECOG performance status score of 2 or lower
- Expected survival longer than 3 months
You will not qualify if you...
- Liver function classified as Child-Pugh grade C or severe jaundice, especially obstructive jaundice
- Significant liver atrophy or tumor size requiring ablation of one-third or more of liver volume
- Expected survival less than 3 months
- Serious dysfunction of heart, lung, liver, kidney, or blood clotting issues
- Uncontrolled health conditions such as hypertension, diabetes, active infections, mental illness, or social issues affecting study compliance
- Refractory ascites, pleural fluid, or other problematic fluid collections
- Pregnancy or breastfeeding
- Any other medical or personal factors deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, Shanghai Municipality, China, 200040
Actively Recruiting
Research Team
L
Long Jiang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here